Jellybelly.......check this out...

Discussion in 'Fibromyalgia Main Forum' started by dojomo, Mar 4, 2003.

  1. dojomo

    dojomo New Member


    LOOK what I found researching.... someone applied for a patent to diagnose CFS ect.....using a list of different studies and tests relating to coagulation irregularities. I didn't copy the whole patent application....but here is the tests they want to include in the panel.
    You can find this and other patent applications at the United States Patent and Trademark using the application number........DJ

    United States Patent Application20020037528 Kind Code A1 Berg, David E. ;   et al. March 28, 2002

    [0004] The current invention relates to a method for diagnosing and identifying genetic and metabolic procoagulant factors that are
    1) associated with hereditary predisposition for activation of the coagulation response, or
    2) occur in patients who have measurable minimal activation of the coagulation response; and whose initial clinical evaluation indicates chronic fatigue syndrome, fibromyalgia, Gulf War illness and related conditions; and whose low level activation of coagulation can be treated using anticoagulant therapies.

    The present invention further identifies underlying procoagulant factors that may

    1) guide treatment of the condition using anticoagulant therapies;
    2) be used to identify asymptomatic family members and close contacts who may be at risk for such disorders and, once identified, may be monitored and treated more effectively given the knowledge of the underlying hereditary genetic and metabolic procoagulant condition.
    [0005] We have previously discovered that we may reliably diagnose a patient suffering from CFS, FM or GWI by evaluating the status of the coagulation response in that patient by using a novel combination of tests which can detect minimal activation of the coagulation response. This novel combination includes tests for determining levels of:

    prothrombin fragment 1+2, thrombin/antithrombin complexes,
    soluble fibrin monomer,
    and platelet activation by flow cytometry.

    These assays are highly sensitive to minimal deviation from normal. Deviation from the normal values in any two of the five assays permits diagnosis of CFS, FM, GWI or other disease associated with activation of the coagulation response.

    Once a condition associated with activation of the coagulation response has been diagnosed, the patient is treated with anticoagulant therapy, such as heparin followed by warfarin or warfarin alone. Coumarins or coumarin derivatives may also be used. Heparin can be defined as heparin (porcine or bovine) or any of its derivatives, such as low molecular weight heparin (LMWH), oral heparin, heparinoids, or any other designer heparin-like drugs. It is presently preferred that a low dose anticoagulant therapy be used. Patient progression and recovery is then monitored using the novel combination of assays.

    We have observed that a majority of individuals diagnosed as CFS and/or FM on clinical criteria may be defined as having an antiphospholipid antibody syndrome (APS) that is induced or generated by pathogens that invade endothelial cells and induce antibodies that can trigger the low level activation of coagulation that we detect.In addition, patients with immune-mediated chronic inflammatory disorders of many types can have low level activation of the coagulation response.

    Therefore, patients with a spectrum of chronic inflammatory processes may have low level activation of coagulation as part of their pathophysiology. We postulate that our tests for activation of the coagulation and platelet systems also have application to other conditions which stem from activation of the coagulation response. This has been validated by preliminary studies of patients suffering with multiple sclerosis, breast implant sickness syndrome, fetal wastage syndrome, gulf war illness, inflammatory bowel disease, autism.

    As with CFS and FM, once diagnosed using our combination of assays, these patients may be treated with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests.

    Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.[This Message was Edited on 03/04/2003]
  2. dojomo

    dojomo New Member

    I don't quite understand how you can patent bloodwork in this way... but if they recieve a patent and go public put me in for a million!!!..........DJ